<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1800">
  <stage>Registered</stage>
  <submitdate>8/03/2007</submitdate>
  <approvaldate>8/03/2007</approvaldate>
  <nctid>NCT00602004</nctid>
  <trial_identification>
    <studytitle>Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan</studytitle>
    <scientifictitle>Early and Late Cardiac Effects of Arteriovenous Fistula Creation for Haemodialysis in End-stage Renal Failure and Their Possible Attenuation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2006.059</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Renal Failure</healthcondition>
    <healthcondition>Left Ventricular Hypertrophy</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - losartan

Treatment: drugs: losartan
losartan 50 mg a day

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>left ventricular hypertrophy</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Diagnosis of CKD at near-end stage renal failure (CKD Stage IV) ( eGFR = 15-30
             mls/min).

          2. Age &gt;18 years of age and &lt;85 years of age.

          3. Males and post-menopausal, sterile women. Non-pregnant pre-menopausal women should be
             on adequate contraception and have no intention of becoming pregnant during the
             duration of the study.

          4. At baseline TTE LVEF&gt;45%

          5. Willing and able to give informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Serum potassium level of more than 5.5 mmol/L

          2. Acute myocardial infarction or cerebrovascular accident in the previous 6 months.

          3. Severe uncontrolled hypertension (diastolic BP &gt;100mmHg or systolic BP &gt;160 mmHg)

          4. Evidence or suspicion of renovascular disease.

          5. Atrial fibrillation

          6. Evidence or suspicion of collagen disease, cancer, psychiatric disorder that
             interferes with patient compliance, drug or alcohol abuse, pregnancy, breast feeding
             and ineffective contraception.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>52</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode>3150 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective is to determine if the use of losartan, an angiotensin II receptor
      blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive
      effects, in patients with near end stage chronic kidney disease (CKD) who have an
      arteriovenous fistula created.

      Secondary outcomes include the impact of the medication on BNP and hyperkalaemia</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00602004</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Anuradha Aggarwal</name>
      <address>Melbourne Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>